1 | Duecravacitinib | Duecravacitinib | LC-MS/MS | Human Plasma | 0.1 to 600 |
2 | Metformin + Sitagliptin + Glimepiride | Metformin + Sitagliptin + Glimepiride | LC-MS/MS | Human Plasma | 15 to 4000, 3 to 900, 1 to 300 |
3 | Imeglimin + Sitagliptin + Glimepiride | Imeglimin + Sitagliptin + Glimepiride | LC-MS/MS | Human Plasma | 10 to 3000, 3 to 900, 1 to 300 |
4 | Duecravacitinib | Duecravacitinib | LC-MS/MS | Rat Plasma | 0.1 to 600 |
5 | Metformin | Metformin | LC-MS/MS | Human Plasma | 10 to 2000 |
6 | Sitagliptin | Sitagliptin | LC-MS/MS | Human Plasma | 2 to 800 |
7 | Metformin + Sitagliptin | Metformin + Sitagliptin | LC-MS/MS | Human Plasma | 10 to 2000, 4 to 800 |
8 | Sitagliptin + Glimepiride | Sitagliptin + Glimepiride | LC-MS/MS | Human Plasma | 3 to 900, 1 to 300 |
9 | Metformin + Glimepiride | Metformin + Glimepiride | LC-MS/MS | Human Plasma | 10 to 3000, 1 to 300 |
10 | Metformin + Linagliptin | Metformin + Linagliptin | LC-MS/MS | Human Plasma | 10 to 2000, 0.1 to 20 |
11 | Linagliptin + Glimepiride | Linagliptin + Glimepiride | LC-MS/MS | Human Plasma | 0.1 to 20, 1 to 300 |
12 | Valsartan + Sacubitril | Valsartan + Sacubitril | LC-MS/MS | Human Plasma | 25 to 10000, 15 to 6000 |
13 | Nicotine | Nicotine | LC-MS/MS | Human Plasma | 0.2 to 40 |
14 | Fruquintinib | Fruquintinib | LC-MS/MS | Human Plasma | 0.1 to 400 |
15 | Vildagliptin + Dapagliflozin | Vildagliptin + Dapagliflozin | LC-MS/MS | Human Plasma | 1 to 500, 1 to 200 |
16 | Rosuvastatin | Rosuvastatin | LC-MS/MS | Human Plasma | 0.2 to 60 |
17 | Rosuvastatin + Sitagliptin | Rosuvastatin + Sitagliptin | LC-MS/MS | Human Plasma | 0.2 to 60, 3 to 900 |
18 | Rosuvastatin + Linagliptin | Rosuvastatin + Linagliptin | LC-MS/MS | Human Plasma | 0.2 to 60, 0.1 to 20 |
19 | Metformin + Linagliptin + Glimepiride | Metformin + Linagliptin + Glimepiride | LC-MS/MS | Human Plasma | 10 to 2000, 0.1 to 20, 1 to 300 |
20 | Metformin + Linagliptin + Dapagliflozin | Metformin + Linagliptin + Dapagliflozin | LC-MS/MS | Human Plasma | 10 to 2000, 0.1 to 20, 1 to 300 |
21 | Metformin + Dapagliflozin | Metformin + Dapagliflozin | LC-MS/MS | Human Plasma | 10 to 2000, 1 to 200 |
22 | Bilastine + Montelukast | Bilastine + Montelukast | LC-MS/MS | Human Plasma | 4 to 1000, 4 to 1000 |
23 | Valsartan + Sacubitril + Dapagliflozin | Valsartan + Sacubitril + Dapagliflozin | LC-MS/MS | Human Plasma | 25 to 10000, 15 to 6000, 1 to 200 |
24 | Eltrombopag | Eltrombopag | LC-MS/MS | Human Plasma | 20 to 8000 |
25 | Didrogesterone | Didrogesterone | LC-MS/MS | Human Plasma | 0.05 to 60 |
26 | Nicotinuric acid Pacritinib | Pacritinib | LC-MS/MS | Rat Plasma | 10 to 6000 |
27 | Nirmatrelvir | Nirmatrelvir | LC-MS/MS | Human Plasma | 5 to 3000 |
28 | Capmatinib | Capmatinib | LC-MS/MS | Human Plasma | 5 to 3000 |
29 | Elagolix | Elagolix | LC-MS/MS | Human Plasma | 5 to 2000 |
30 | Bisacodyl | Bisacodyl + Deacetyl Bisacodyl | LC-MS/MS | Human Plasma | 0.02 to 6 |
31 | Bisacodyl | Bisacodyl + Deacetyl bisacodyl + Deacetyl Bsacodyl b-D-Glucuronide | LC-MS/MS | Human Plasma | 0.02 to 6, 0.02 to 6, 0.2 to 100 |
32 | Montelukast | Montelukast | LC-MS/MS | Human Plasma | 2 to 700 |
33 | Amoxicillin | Amoxicillin | LC-MS/MS | Human Plasma | 125 to 30000 |
34 | Tamsulosin | Tamsulosin | LC-MS/MS | Human Plasma | 0.1 to 20 |
35 | Gliclazide | Gliclazide | LC-MS/MS | Human Plasma | 15 to 6500 |
36 | Ferric maltol | Total Serum Iron | Spectrophotometer | Human Serum | 400 to 10000 |
37 | Ramipril | Ramipril and Ramiprilate | LC-MS/MS | Human Plasma | Under development |
38 | Transferrin bound Iron | Transferrin bound Iron | Spectrophotometer | Human Serum | Under development |
39 | Avatrombopag | Avatrombopag | LC-MS/MS | Rat Plasma | Under development |